MSCV-MYC-t2A-BCL2 Citations (1)

Originally described in: Genetic modification of primary human B cells to model high-grade lymphoma.
Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias JML, Cooke SL, Fenner R, Usheva Z, Runge HFP, Beer PA, Eldaly H, Pak HK, Park CS, Vassiliou GS, Huntly BJP, Mupo A, Bashford-Rogers RJM, Hodson DJ Nat Commun. 2019 Oct 4;10(1):4543. doi: 10.1038/s41467-019-12494-x. PubMed Journal

---

Articles Citing MSCV-MYC-t2A-BCL2

Articles

Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes. Dreute J, Stengel J, Becher J, van den Borre D, Pfisterer M, Bartkuhn M, Beutgen VM, Ndreshkjana B, Gartner U, Graumann J, Huck M, Klatt S, Leff C, Farin HF, Nist A, Schmitz R, Stiewe T, Teply-Szymanski J, Wilhelm J, Cabrera-Orefice A, Schmitz ML. Cell Death Differ. 2025 Jun 23. doi: 10.1038/s41418-025-01532-5. PubMed

If you have published an article using this material, please email us at to have your article added to this page.